Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 485750, 10 pages
http://dx.doi.org/10.1155/2012/485750
Research Article

Lactococcus lactis NCC 2287 Alleviates Food Allergic Manifestations in Sensitized Mice by Reducing IL-13 Expression Specifically in the Ileum

1Allergy Group, Department of Nutrition and Health, Nestle Research Center, Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland
2CSL Behring AG, Wankdorfstraße 10, 3010 Bern 22, Switzerland
3Applied Mathematics Group, Department of Bio-Analytical Sciences, Nestle Research Center, Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland
4Stallergènes SA, Research and Development, 6 rue Alexis de Tocqueville, 92183 Antony, France

Received 13 May 2011; Accepted 21 July 2011

Academic Editor: Daniel Mucida

Copyright © 2011 Adrian W. Zuercher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. Utilizing a food allergy murine model, we have investigated the intrinsic antiallergic potential of the Lactococcus lactis NCC 2287 strain. Methods. BALB/c mice were sensitized at weekly intervals with ovalbumin (OVA) plus cholera toxin (CT) by the oral route for 7 weeks. In this model, an oral challenge with a high dose of OVA at the end of the sensitization period leads to clinical symptoms. Lactococcus lactis NCC 2287 was given to mice via the drinking water during sensitization (prevention phase) or after sensitization (management phase). Results. Lactococcus lactis NCC 2287 administration to sensitized mice strikingly reduced allergic manifestations in the management phase upon challenge, when compared to control mice. No preventive effect was observed with the strain. Lactococcus lactis NCC 2287 significantly decreased relative expression levels of the Th-2 cytokine, IL-13, and associated chemokines CCL11 (eotaxin-1) and CCL17 (TARC) in the ileum. No effect was observed in the jejunum. Conclusion/Significance. These results taken together designate Lactococcus lactis NCC 2287 as a candidate probiotic strain appropriate in the management of allergic symptoms.